kintor pyrilutamide clinical trials


Hair loss affects millions of people worldwide, impacting not only physical appearance but also psychological well-being. Amidst the quest for effective treatments, Pyrilutamide has emerged as a promising contender. With its antiandrogenic properties, Pyrilutamide holds potential in mitigating hair loss by inhibiting the effects of androgens on hair follicles. The latest clinical trials investigating Pyrilutamide’s efficacy and safety in managing hair loss shed light on its role as a novel therapeutic option. This article delves into the evolving landscape of Pyrilutamide research, providing insights from recent clinical trials and exploring its potential as a game-changer in the field of hair loss treatment.


Pyrilutamide is a promising compound under investigation for its potential to address hair loss, particularly androgenetic alopecia, commonly referred to as male and female pattern hair loss. Belonging to the class of medications known as androgen receptor antagonists, Pyrilutamide works by blocking androgen receptors in the hair follicles. This action inhibits the effects of dihydrotestosterone (DHT), a hormone linked to hair follicle miniaturization and loss in those genetically predisposed to hair thinning. By impeding DHT from binding to these receptors, Pyrilutamide aims to interrupt the hair loss process and potentially stimulate hair retention and regrowth. However, it’s important to note that research on Pyrilutamide for hair loss is ongoing, and further data on its effectiveness, safety, and potential side effects may emerge over time.


Pyrilutamide is a novel compound under investigation for its potential in treating hair loss. It operates through various mechanisms to target the underlying causes of hair follicle miniaturization and hair loss. While specific details regarding its mode of action may still be under research, several potential mechanisms have been proposed based on its properties and effects.

One potential mode of action of Pyrilutamide involves its ability to modulate androgen receptors in the scalp. Androgens, particularly dihydrotestosterone (DHT), play a significant role in the miniaturization of hair follicles in individuals with androgenetic alopecia. By interacting with androgen receptors, Pyrilutamide may disrupt the binding of DHT to these receptors, thereby mitigating the adverse effects of DHT on hair follicles and potentially promoting hair growth and retention.

Moreover, Pyrilutamide may exert anti-inflammatory effects on the scalp. Inflammation is believed to contribute to the progression of hair loss by disrupting the normal hair growth cycle and damaging hair follicles. By reducing inflammation in the scalp, Pyrilutamide may create a more conducive environment for hair follicle health and support optimal conditions for hair growth.

Additionally, Pyrilutamide might influence various molecular pathways involved in hair follicle regeneration and growth. This could include stimulating the proliferation and differentiation of hair follicle stem cells, promoting the transition of hair follicles from the resting phase (telogen) to the growth phase (anagen), and enhancing the production of growth factors essential for hair growth.

Overall, while specific details of Pyrilutamide’s mode of action for hair loss may require further research and clarification, its potential mechanisms include modulating androgen receptors, reducing scalp inflammation, and influencing molecular pathways involved in hair follicle regeneration and growth. Further studies are necessary to fully elucidate its efficacy and safety profile for treating hair loss.


Phase 1/1b Clinical Trials:

Recently, a phase-1 clinical trial was conducted in the United States, following a randomized, double-blind, placebo-controlled, parallel-group, and dose-escalation design. This trial enrolled 40 healthy adult male participants diagnosed with androgenetic alopecia.

The primary objective of this clinical study was to assess the safety, tolerability, and pharmacokinetics of pyrilutamide, a topical androgen receptor antagonist. The participants received multiple ascending doses of pyrilutamide, ranging from 3mg to 96mg.

Throughout the study, the blood concentration of pyrilutamide among the subjects remained remarkably low. Importantly, no severe adverse drug events were reported, indicating a favorable safety profile associated with pyrilutamide.

Phase 2 Clinical Trials:

Multiple clinical trials have been conducted in both China and the United States to evaluate the efficacy of pyrilutamide in treating hair loss. In 2020, the first phase 2 clinical trial took place in China, involving a multi-regional randomized placebo-controlled study. This trial included 120 male subjects diagnosed with androgenetic alopecia, who were randomly assigned to four dose groups: 2.5 mg (0.25%) of pyrilutamide twice a day, 5.0 mg (0.5%) once a day, 5.0 mg (0.5%) twice a day, and a placebo group. The primary outcome measured was the change in non-vellus target area hair count (TAHC) from baseline after six months of treatment.

Participants receiving pyrilutamide 0.5% solution applied twice daily demonstrated a statistically significant improvement in total area hair count compared to the placebo group. Specifically, there was an increase of 22.73 hairs per cm2 in the pyrilutamide group, whereas the placebo group only experienced an increase of 15.34 hairs per cm2. Based on these promising results, the 0.5% pyrilutamide solution was selected for further investigation in phase 3 clinical trials.

In December 2022, another phase 2 clinical study focusing on the treatment of female pattern hair loss (female AGA) was published. This study included 119 female subjects with AGA who were randomly assigned to four treatment groups with varying doses of pyrilutamide. Results indicated that the pyrilutamide 0.5% solution applied once daily significantly increased hair count by 11.39 hairs per cm2 from baseline after 24 weeks of treatment, with improvements observed as early as the end of week 12. Similar to previous phase 2 trials, pyrilutamide exhibited a favorable safety profile.

The most recent phase 2 trial conducted in the United States reported its results in May 2023. This trial was a randomized, double-blind, placebo-controlled study involving 123 male patients with male pattern alopecia. The study demonstrated an increase in target area hair count by approximately 10 hairs per cm2 from baseline after 24 weeks of treatment with the 0.5% pyrilutamide solution applied twice daily. The results were both statistically and clinically meaningful, demonstrating a favorable safety profile. The company plans to proceed with subsequent FDA meetings on the Phase 2 trial results and initiate Phase 3 clinical trials in the United States and globally.

Phase 3 Clinical Trials:

In November 2021, the Phase 3 clinical trial protocol for evaluating pyrilutamide as a treatment for male androgenetic alopecia received approval. This trial is a randomized, double-blind, placebo-controlled, multi-regional study set to take place across 26 dermatology centers in China.

As of March 2023, a total of 740 male patients have been enrolled in this extensive study. Its primary objective is to assess the efficacy and safety profile of pyrilutamide in addressing male pattern hair loss. The trial is scheduled to run for a duration of 24 weeks with an additional 4-week follow-up period. The primary endpoint of the study is to observe the change in non-vellus target area hair count (TAHC) from baseline at the conclusion of week 24.


In conclusion, the clinical trial results for pyrilutamide offer promising insights into its potential as a treatment for androgenetic alopecia. Through rigorous phase 1/1b, phase 2, and ongoing phase 3 trials, pyrilutamide has demonstrated encouraging efficacy in promoting hair growth among male and female participants with varying degrees of hair loss. The favorable safety profiles observed across these studies further underscore the potential of pyrilutamide as a viable therapeutic option for addressing hair loss. With continued research and evaluation, pyrilutamide holds the promise of providing individuals grappling with androgenetic alopecia with a safe and effective solution to combat hair loss.

Hair loss products in a row

Leave a Comment

Your email address will not be published. Required fields are marked *